Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential

Blood

Volumn 116, Issue 22, 2010, Pages 4542-4545

  Delluc, Stéphanie ^a   Ravot, Gilles ^a   Maillere, Bernard ^b  

^a Parc Georges Besse   (France)

^b DIF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ARTICLE; CD4+ T LYMPHOCYTE; CELL STIMULATION; HUMAN; HUMAN CELL; HUMORAL IMMUNE DEFICIENCY; IMMUNOGENICITY; NORMAL HUMAN; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUANTITATIVE ANALYSIS;

EID: 78649486646     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-280875     Document Type: Article

References (24)

1. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469-475.
2. Villalobos AP, Gunturi SR, Heavner GA. Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions. Pharm Res. 2005;22(7):1186-1194.
3. Schellekens H, Jiskoot W. Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol. 2006;3(3):123-130.
4. Ryan MH, Heavner GA, Brigham-Burke M, et al. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int Immunopharmacol. 2006;6(4):647-655.
5. + T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood. 2003;101(4):1351-1358.
6. Bray GL, Kroner BL, Arkin S, et al. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol. 1993;42(4):375-379.
7. Yeung VP, Chang J, Miller J, Barnett C, Stickler M, Harding FA. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol. 2004;172(11):6658-6665.
8. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science. 1990;248(4961):1349-1356.
9. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
10. Schlienger K, Craighead N, Lee KP, Levine BL, June CH. Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. Blood. 2000;96(10):3490-3498.
11. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406(6797):782-787.
12. De Gregorio E, D'Oro U, Wack A. Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol. 2009;21(3):339-345.
13. Hemmi H, Kaisho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3(2):196-200.
14. Mueller R, Karle A, Vogt A, et al. Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout. J Pharm Sci. 2009;98(10):3548-3561.
15. Lotz M, Ebert S, Esselmann H, et al. Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. J Neurochem. 2005;94(2):289-298.
16. Skopeliti M, Iconomidou VA, Derhovanessian E, et al. Prothymosin alpha immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner. Mol Immunol. 2009;46(5):784-792.
17. Cibotti R, Kanellopoulos JM, Cabaniols JP, et al. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci U S A. 1992;89(1):416-420.
18. Peterson DA, DiPaolo RJ, Kanagawa O, Unanue ER. Quantitative analysis of the T cell repertoire that escapes negative selection. Immunity. 1999;11(4):453-462.
19. Castelli FA, Leleu M, Pouvelle-Moratille S, et al. Differential capacity of T cell priming in naive donors of promiscuous CD4(+) T cell epitopes of HCV NS3 and Core proteins. Eur J Immunol. 2007;37(6):1513-1523.
20. Tangri S, Mothe BR, Eisenbraun J, et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol. 2005;174(6):3187-3196.
21. Geiger R, Duhen T, Lanzavecchia A, Sallusto F. Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med. 2009;206(7):1525-1534.
22. Ohashi PS, Oehen S, Buerki K, et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 1991;65(2):305-317.
23. Cabaniols JP, Cibotti R, Kourilsky P, Kosmatopoulos K, Kanellopoulos JM. Dose-dependent T cell tolerance to an immunodominant self-peptide. Eur J Immunol. 1994;24(8):1743-1749.
24. Haribhai D, Engle D, Meyer M, Donermeyer D, White JM, Williams CB. A threshold for central T cell tolerance to an inducible serum protein. J Immunol. 2003;170(6):3007-3014.